Metabolic syndrome and coronary heart disease
- 作者: Gurgenian S1, Vatinian S1, Zelveian P2
-
隶属关系:
- НИИ кардиологии им. Л. Оганесяна, Ереван, Армения
- Национальный институт здравоохранения Армении
- 期: 卷 86, 编号 3 (2014)
- 页面: 106-110
- 栏目: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/31499
- ID: 31499
如何引用文章
全文:
详细
The literature review presents current views on micro- and macrovascular disorders in metabolic syndrome characterized by silent myocardial ischemia detectable only during exercise and myocardial radionuclide scintigraphy.
作者简介
S Gurgenian
НИИ кардиологии им. Л. Оганесяна, Ереван, Армения
Email: goorggenyan@mail.ru
S Vatinian
НИИ кардиологии им. Л. Оганесяна, Ереван, Армения
Email: marsjurist@rambler.ru
P Zelveian
Национальный институт здравоохранения Армении
Email: zelveian@hotmail.com
参考
- McNeill A.M., Rosamond W.D., Girman C.J. et al. Prevalence of coronary heart disease and carotid arterial thickening in patients with the metabolic syndrome (The ARIC Study). Am J Cardiol 2004; 94: 1249-1254.
- International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Accessed March 13, 2006.
- Yusuf S., Hawken S., Ounpuu S. et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-952.
- Saely C., Aczel S., Marte T. et al. The Metabolic Syndrome, Insulin Resistance, and Cardiovascular Risk in Diabetic and Nondiabetic Patients. J Clin Endocrin Metabol 2005; 90: 5698-5703.
- Kannel W.B. Lipids, diabetes and coronary heart disease: insights from the Framingham Study. Am Heart J 1985; 110: 1100-1107.
- Pen A., Yam Y., Chen L. et al. Discordance between Framingham Risk Score and atherosclerotic plaque burden. Eur Heart J 2013; 34: 1075-1082.
- Montecucco F., Vuilleumier N., Pagano S. et al. Anti-apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability. Eur Heart J 2011; 32: 412-421.
- Nigro J., Osman N., Dart A. et al. Insulin Resistance and Atherosclerosis. Endocrine Rev 2006; 27 (3): 242-259.
- Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126.
- Williams K., Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995; 15: 551-561.
- Williams K., Tabas I. The response-to-retention hypothesis of atherogenesis reinforced. Curr Opin Lipidol J 1998; 9: 471-474.
- Skalen K., Gustafsson M., Rydberg E. et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002; 417: 750-754.
- Witztum J.H. The oxidative hypotheses of atherosclerosis. Lancet 1994; 344: 793-795.
- Blankenberg S., Barbaux S., Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis 2003; 170: 191-203.
- Roganec K.S., Ulrich C., Blomer L. et al. Monocyte heterogeneity in obesity and subclinical atherosclerosis. Eur Heart J 2010; 31: 369-376.
- Fortuno A., Jose G., Moreno M. et al. Oxidative stress and vascular remodeling. Exp Physiol 1997; 6: 305-311.
- Zeiher A., Drexler H., Wollschlager H. et al. Endothelial dysfunction of the coronary microvasculature is associated with coronary blood flow regulation in patients with early atherosclerosis. Circulation 1991; 84: 1984-1992.
- Mogenson C.E. Hypertension and diabetes. Lippincott Williams & Wilkins. 2002.
- Prior J., Quiñones M., Hernandez-Pampaloni M. et al. Coronary Circulatory Dysfunction in Insulin Resistance, Impaired Glucose Tolerance, and Type 2 Diabetes Mellitus. Circulation 2005; 111: 2291-2298.
- Шевченко О.П., Праскурничий Е.А., Шевченко А.О. Метаболический синдром. М: Реафарм 2004.
- Mondorf U., Russ A., Wiesemann A. et al. Contribution of angiotensin I converting enzyme gene polymorphism and angiotensinogen gene polymorphism to blood pressure regulation in essential hypertension. J Hypertens 1998; 11: 174-183.
- Georgiou I., Elisaf M., Siamopoulos K. et al. Impact of renin-angiotensin-aldosterone system genes on the treatment response of patients with hypertension and metabolic syndrome. J Renin Angiotensin Aldosterone Syst 2007; 8: 181.
- Weiss D., Kools J., Taylor W. Angiotensin II-induced hypertension acceleration the development of atherosclerosis in apoE-deficient mice. Circulation 2001; 103: 448-454.
- Golden S. Prevention of coronary heart disease in metabolic syndrome and diabetes mellitus. Advanced Studies in Pharmacy 2002; 2: 364-371.
- Mykkanen L., Kuusisto J., Pyorala K. Cardiovascular disease risk factors as predictors of type 2 (non-insulin dependent) diabetes mellitus in elderly subjects. Diabetologia 1993; 36: 553-559.
- Deedwania P. Metabolic Syndrome and Vascular Disease. Is Nature or Nurture Leading the New Epidemic of Cardiovascular Disease? Circulation 2004; 109: 2-4.
- Assmann G., Schulte G. The Prospective Cardiovascular Munster study prevalence and prognostic significance of hyperlipidemia in men with systemic hypertension. Am J Cardiol 1987; 59: 9G-17G.
- Assmann G., Schulte G. The Prospective Cardiovascular Munster (PROCAM) study: prevalence of hyperlipidemia in persons hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J 1988; 116: 1713-1724.
- Assmann G., Schulte G. Relation high density lipoprotein cholesterol and triglicerides tj incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol 1992; 70: 733-737.
- Трубецкой А.В. Регуляция коронарного кровообращения. Руководство по кардиологии. Под ред. Е.И. Чазова. М: Медицина 1982; 240-248.
- Selye H. The stress of life. New York: McGraw-Hill 1975.
- Хехт А. Введение в экспериментальные основы современной патологии сердечной мышцы. М: Медицина 1975.
- Shea T.M., Watson R.M.., Piotrowski S.F. et al. Anaerobic myocardial metabolism. Am J Physiol 1962; 203: 463-469.
- Després J.P., Lemieux I., Dagenais G.R. et al. HDL-cholesterol is a marker of coronary heart disease in the Quebec Cardiovascular Study. Atherosclerosis 2000; 153: 263-272.
- Dale A., Nilsen T., Vatten L. et al. Diabetes mellitus and risk of fatal ischeamic heart disease by gender: 18-year follow-up of 94914 individuals in the HUNT 1 Study. Eur Heart J 2007; 28: 2924-2929.
- Stanley W., Ryden L. The Diabetic Coronary Patient. London: Science Press Ltd 1999.
- Efstratopoulos V.S., Hatzis G.T., Mougros B.A. Left ventricular hypertrophy аnd coronary heart disease in patients with metabolic syndrome and arterial hypertension. Hippokratia 2004; 8: 69-72.
- Dale A., Midtcjell K., Nilsen T. et al. Glycaemic control in newly diagnosed diabetes patients and mortality from ischaemic heart disease: 20-year follow-up of the NUNT Study in Norway. Eur Heart J 2009; 30: 1372-1377.
- Barnes E., Camici P. Diagnosis of heart disease in diabetes: new insights into myocardial insulin resistance. In: The Diabetic Coronary Patient. London: Science Press Ltd 1999.
- Galderisi M., Cicala S., Caso P. et al. Coronary flow reserve and myocardial diastolic dysfunction in arterial hypertension. Am J Cardiol 2002; 90: 860-864.
- Ammar R., Dellsperger K. Соronary artery disease in diabetes. In: The diabetic coronary patient. London: Science Press Ltd 1999.
- Niaura R., Todaro J., Stroud L. et al. Hostility, the metabolic syndrome, and incident coronary heart disease. Health Psychol 2002; 21: 588-593.
- Butler K.R., Macdonald T.M., Strutners A.D. et al. The clinical implication of diabetic heart disease. Eur Heart J 1998; 19: 1617-1627.
- Dortimer A., Shenoy P., Shiroff R. Diffuse coronary disease in diabetics; fact or fiction? Circulation 1978; 57: 133-136.
- Butler K.R. Hemoglobin levels, cardiovascular disease, and left ventricular hypertrophy in patients with chronic kidney disease. Case study of the anemic patient. Nephrol Nurs J 2002; 29: 189.
- Burgess D.C., Hunt D., Li L. Incidence and predictions of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Eur Heart J 2011; 31: 92-99.
- Herlitz J., Malmberg K., Karlson B. et at. Mortality and morbidity during a five-year follow-up of diabetics with myocardial infarctions. Acta Med Scand 1988; 224: 31-38.
- Sundstrom J. Left ventricular hypertrophy and the insulin resistance syndrome. Acta Universitatis Upsaliensis 2001; 992: 68.
- Mouguet F., Cuileret F., Susen S. et al. Metabolic syndrome and collateral vessel formation in patients with documented occluded coronary arteries: associated with hyperglycemia/insulin-resistance, adiponectin and plasminogen activator inhibitor-1. Eur Heart J 2009; 30: 840-849.
- Shehadeh A., Regan T. Cardiac consequences of diabetes mellitus. Clin Cardiol 1995; 18: 301-305.
- Iwasaka T., Takahashi N., Nakamura S. et al. Residual left ventricular pump dysfunction after acute myocardial infarction in NIDDM patients. Diab Care 1992; 15: 1522-1526.